FDA Orange Book · active-ingredient family
Baxdrostat
Baxdrostat is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:BAXFENDY · NDA 219878
1
Brand (NDA)
0
Generics (ANDA)
1
Listed patents
2
Exclusivity periods
Brand (NDA) products · tablet
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| BAXFENDYRLD×2 | ASTRAZENECA AB | NDA 219878 | — | May 15, 2026 |
Marketing exclusivity (2)
- NCENew chemical entity exclusivity (5 years)
May 15, 2031
in 5 yr
- NCENew chemical entity exclusivity (5 years)
May 15, 2031
in 5 yr
Listed patents (1)
| Patent | Expires | In | Type |
|---|---|---|---|
| 9353081 | Feb 04, 2033 | in 6 yr 9 mo | SubstanceProduct |
Baxdrostat — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

